Here are the 10-K annual reports from GlucoTrack Inc New (GCTK) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GCTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GCTK filings page.
Glucotrack, Inc. files its annual report describing a development-stage medical device business focused on an implantable continuous blood glucose monitor (Glucotrack CBGM) for Type 1 and insulin-using Type 2 diabetes patients.
The company reports multiple successful preclinical and early human studies, ISO 13485 certification, and active FDA presubmission discussions toward an Investigational Device Exemption and a planned U.S. feasibility study in 2026. It highlights a large global diabetes market and unmet needs around convenience, wear-time, and comfort versus current CGM systems.
Financially, Glucotrack remains pre-revenue with net losses of about $19.4 million in 2025 and an accumulated deficit of $151.8 million, ending 2025 with $7.4 million in cash. Management and auditors raise substantial doubt about the company’s ability to continue as a going concern without additional capital, and the filing emphasizes significant regulatory, clinical, competitive, and reimbursement risks.